Stock Events

Stock Events

Inventiva 

$5.47
58
+$0.04+0.74% Today

Statistics

Day High
5.63
Day Low
5.27
52W High
7.98
52W Low
2.85
Volume
321,272
Avg. Volume
450,009
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30MarExpected
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-2.14
-1.43
-0.71
0
Expected EPS
-1.66
Actual EPS
-2.14

Financials

-1,230.25%Profit Margin
Unprofitable
2015
2016
2017
2018
2019
2020
2.31MRevenue
-28.37MNet Income

Analyst Ratings

$14.17Average Price Target
The highest estimate is 24.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IVA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Galapagos NV
GLPG
Mkt Cap2.09B
Galapagos NV focuses on developing novel modes of action, including fibrosis treatments, competing in the same therapeutic areas as Inventiva.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Madrigal Pharmaceuticals is involved in developing solutions for nonalcoholic steatohepatitis (NASH), a key area of focus for Inventiva.
Viking Therapeutics
VKTX
Mkt Cap4.3B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a competitor.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a broad portfolio that includes treatments for liver diseases, such as NASH, competing with Inventiva's pipeline.
Agenus
AGEN
Mkt Cap126.5M
Agenus Inc. is focused on immuno-oncology but its interest in novel therapeutic approaches can indirectly compete with Inventiva's innovative treatments.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a diverse biopharmaceutical portfolio that includes research in fibrosis, making it a competitor.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad research portfolio that includes fibrosis and other areas relevant to Inventiva's interests.
Novartis
NVS
Mkt Cap237.61B
Novartis AG conducts extensive research in areas including fibrosis and metabolic diseases, overlapping with Inventiva's therapeutic areas.

About

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Show more...
CEO
Dr. Pierre Broqua Ph.D.
Employees
114
Country
MY
ISIN
US46124U1079

Listings

XETRA
DE
6IV.XETRA
F
DE
6IVA.F
PA
FR
IVA.PA
XNAS
US
IVA

0 Comments

Share your thoughts

FAQ

What is Inventiva stock price today?▼
The current price of IVA is $5.47 USD — it has increased by +0.74% in the past 24 hours. Watch Inventiva stock price performance more closely on the chart.
What is Inventiva stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Inventiva stocks are traded under the ticker IVA.
Is Inventiva stock price growing?▼
IVA stock has fallen by -10.18% compared to the previous week, the month change is a -13.04% fall, over the last year Inventiva has showed a +76.45% increase.
When is the next Inventiva earnings date?▼
Inventiva is going to release the next earnings report on September 25, 2026.
What were Inventiva earnings last quarter?▼
IVA earnings for the last quarter are -2.14 USD per share, whereas the estimation was -1.66 USD resulting in a -28.92% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Inventiva revenue for the last year?▼
Inventiva revenue for the last year amounts to 2.31M USD.
What is Inventiva net income for the last year?▼
IVA net income for the last year is -28.37M USD.
How many employees does Inventiva have?▼
As of April 02, 2026, the company has 114 employees.
In which sector is Inventiva located?▼
Inventiva operates in the Health Care sector.
When did Inventiva complete a stock split?▼
Inventiva has not had any recent stock splits.
Where is Inventiva headquartered?▼
Inventiva is headquartered in Daix, MY.